Freshly Funded ImCheck Goes After Gamma Delta T-Cells
$53m Series B Financing Will Advance ImCheck Therapeutics’ Pipeline
Executive Summary
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
You may also be interested in...
Finance Watch: Two New VC Funds Raise $755m To Fund Innovation
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Need a specific report? 1000+ reports available
Buy Reports